

SENATE, No. 3696

STATE OF NEW JERSEY
219th LEGISLATURE

INTRODUCED APRIL 26, 2021

Sponsored by:

Senator LINDA R. GREENSTEIN

District 14 (Mercer and Middlesex)

Senator ANTHONY M. BUCCO

District 25 (Morris and Somerset)

SYNOPSIS

Requires pharmacies to provide certain information regarding insulin manufacturer assistance programs.

CURRENT VERSION OF TEXT

As introduced.



(Sponsorship Updated As Of: 4/26/2021)

1 **AN ACT** concerning insulin manufacturer assistance programs and
2 supplementing P.L.2003, c.280 (C.45:14-40 et seq.).

4 **BE IT ENACTED** *by the Senate and General Assembly of the State*
5 *of New Jersey:*

7 1. a. A pharmacy practice site shall:

8 (1) display a notice concerning insulin manufacturer assistance
9 programs, to be created by the Department of Banking and
10 Insurance, at all points of sale; and

11 (2) provide a pamphlet concerning insulin manufacturer
12 assistance programs, to be created by the department, to an
13 individual purchasing a prescription for insulin and any individual
14 requesting a pamphlet.

b. An insulin manufacturer offering an assistance program may inform the department of its intention to be included in the notices and pamphlets.

c. The department shall adopt rules and regulations pursuant to the “Administrative Procedure Act,” P.L.1968, c.410 (C.52:14B-1 et seq.), to effectuate the purposes of this act.

22 2. This act shall take effect on the first day of the sixth month
23 next following the date of enactment, except that the Commissioner
24 of Banking and Insurance may take any anticipatory administrative
25 action in advance as shall be necessary for the implementation of
26 this act.

STATEMENT

31 This bill requires pharmacies to provide certain information
32 regarding insulin manufacturer assistance programs.

Under this bill, a pharmacy practice site will be required to display a notice, created by the Department of Banking and Insurance, concerning insulin manufacturer assistance programs at all points of sale. A pharmacy practice site will also be required to provide a pamphlet, created by the department, concerning the insulin manufacturer assistance programs to any individual purchasing a prescription for insulin, or to any individual requesting a pamphlet. Insulin manufacturers offering an assistance program may inform the department of their intention to be included in the notices and pamphlets.